|
[1] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J].中国癌症杂志,2017,27(9):695-759.DOI:10.19401/j.cnki.1007-3639.2017.09.004.
[2] Shah C, Vicini FA. Breast cancer-related
arm lymphedema: incidence rates, diagnostic techniques, optimal management and
risk reduction strategies[J]. Int J Radiat Oncol Biol Phys, 2011,81(4):907-914.
DOI: 10.1016/j.ijrobp.2011.05.043.
[3] Lotan E, Leader A, Lishner M, et al.
Unrecognized renal insufficiency and chemotherapy-associated adverse effects
among breast cancer patients[J]. Anticancer Drugs, 2012,23(9):991-995. DOI:
10.1097/CAD.0b013e328355dd8a.
[4] 张佳佳,张易.宫颈癌术后下肢中度淋巴水肿延迟治疗的质性研究[J].护理研究,2020,34(2):303-306.DOI:10.12102/j.issn.1009-6493.2020.02.025.
[5] 胡雁.护理研究[M].4版.北京:人民卫生出版社,2016:270.
[6] 何向明,邹德宏.乳腺癌上肢淋巴水肿治疗进展[J].中国肿瘤,2017,26(3):210-213.DOI:10.11735/j.issn.1004-0242.2 017.03.A009.
[7] Ribeiro Pereira ACP, Koifman RJ,
Bergmann A. Incidence and risk factors of lymphedema after breast cancer
treatment: 10 years of follow-up[J]. Breast, 2017,36:67-73. DOI:
10.1016/j.breast.2017.09.006.
[8] 刘宁飞.淋巴水肿诊断与治疗[M].北京:科学出版社,2014:35-37.
[9] Norman SA, Localio AR, Potashnik SL, et
al. Lymphedema in breast cancer survivors: incidence, degree, time course,
treatment, and symptoms[J]. J Clin Oncol, 2009,27(3):390-397. DOI:
10.1200/JCO.2008.17.9291.
[10] Beiki O, Hall P, Ekbom A, et al. Breast
cancer incidence and case fatality among 4.7 million women in relation to
social and ethnic background: a population-based cohort study[J]. Breast Cancer
Res, 2012,14(1):R5. DOI: 10.1186/bcr3086.
[11] 袁坤,常红娟,张瑞芹,等.乳腺癌病人希望水平影响因素和干预措施研究进展[J].护理研究,2020,34(17):3086-3090.DOI:10.12102/j.issn.1009-6493.2020.17.015.
[12] 虞蓉,张雨钰,吴春英,等.维持性血液透析患者自我管理水平与生存质量的相关性研究[J].国际医药卫生导报,2021,27(6):825-828.DOI:10.3760/cma.j.issn.1007-1245.2021.
06.010.
[13] 李伟玲,谌永毅.北美淋巴水肿治疗师培养、认证及对我国的启示[J].护理研究,2020,34(9):1600-1601.DOI:10.12102/j.issn.1009-6493.2020.09.023.
|
